Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $134.0 million.

  • Arcus Biosciences' Non-Current Assets fell 32.37% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.0 million, marking a year-over-year decrease of 32.37%. This contributed to the annual value of $134.0 million for FY2024, which is 49.24% down from last year.
  • As of FY2024, Arcus Biosciences' Non-Current Assets stood at $134.0 million, which was down 49.24% from $264.0 million recorded in FY2023.
  • Over the past 5 years, Arcus Biosciences' Non-Current Assets peaked at $330.0 million during FY2021, and registered a low of $36.5 million during FY2020.
  • Its 3-year average for Non-Current Assets is $210.3 million, with a median of $233.0 million in 2022.
  • In the last 5 years, Arcus Biosciences' Non-Current Assets spiked by 804.68% in 2021 and then plummeted by 49.24% in 2024.
  • Over the past 5 years, Arcus Biosciences' Non-Current Assets (Yearly) stood at $36.5 million in 2020, then spiked by 804.68% to $330.0 million in 2021, then dropped by 29.39% to $233.0 million in 2022, then increased by 13.30% to $264.0 million in 2023, then tumbled by 49.24% to $134.0 million in 2024.